chemie.pr-weitere Angebote: | Energie-Angebote - Strom-Angebote - Gas Angebote
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
26.06.2008 08:40:05
Roche Pharmaceuticals: Basel, Switzerland (ots/PRNewswire) - - Roche Also Announces Start of NCORE Study to Determine Best Length of Treatment in Patients who do not Experience a Rapid Response Roche announced today that the European Commission has ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
- Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks Provides New Treatment Option for Difficult-to-Treat Hepatitis C Patients
- New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response That Comes as Close to a Cure as Possible
- Roche's R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
- New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
- European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients
- Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
- CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
- New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain
- Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
Bankkaufmann - News
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of
Presseportal: Branchenansicht - Chemie
Roche Pharmaceuticals.European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of
politikportal.at: das APA-OTS-Portal für multimediale Presse ...
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of
ots.at: das APA-OTS-Portal für multimediale Presseaussendungen
Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment = 26.06.2008 / 08:09